The human tumor cloning assay in cancer drug development

1983 ◽  
Vol 1 (1) ◽  
Author(s):  
Peter Agre ◽  
ThomasE. Williams
Author(s):  
M.J. Murphy ◽  
R.R. Price ◽  
J.C. Sloman

The in vitro human tumor cloning assay originally described by Salmon and Hamburger has been applied recently to the investigation of differential anti-tumor drug sensitivities over a broad range of human neoplasms. A major problem in the acceptance of this technique has been the question of the relationship between the cultured cells and the original patient tumor, i.e., whether the colonies that develop derive from the neoplasm or from some other cell type within the initial cell population. A study of the ultrastructural morphology of the cultured cells vs. patient tumor has therefore been undertaken to resolve this question. Direct correlation was assured by division of a common tumor mass at surgical resection, one biopsy being fixed for TEM studies, the second being rapidly transported to the laboratory for culture.


Author(s):  
Lauren Marshall ◽  
Isabel Löwstedt ◽  
Paul Gatenholm ◽  
Joel Berry

The objective of this study was to create 3D engineered tissue models to accelerate identification of safe and efficacious breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and costs associated with development and regulatory approval of anti-cancer therapies, currently a multi-billion dollar endeavor [1]. Existing two-dimensional (2D) in vitro and in vivo animal studies required for identification of effective cancer therapies account for much of the high costs of anti-cancer medications and health insurance premiums borne by patients, many of whom cannot afford it. An emerging paradigm in pharmaceutical drug development is the use of three-dimensional (3D) cell/biomaterial models that will accurately screen novel therapeutic compounds, repurpose existing compounds and terminate ineffective ones. In particular, identification of effective chemotherapies for breast cancer are anticipated to occur more quickly in 3D in vitro models than 2D in vitro environments and in vivo animal models, neither of which accurately mimic natural human tumor environments [2]. Moreover, these 3D models can be multi-cellular and designed with extracellular matrix (ECM) function and mechanical properties similar to that of natural in vivo cancer environments [3].


1986 ◽  
Vol 22 (3) ◽  
pp. 245-249 ◽  
Author(s):  
P. Dodion ◽  
C. Sanders ◽  
W. Rombaut ◽  
M. Rozencweig ◽  
M.M. Kitt ◽  
...  

1985 ◽  
Vol 21 (2) ◽  
pp. 195-198 ◽  
Author(s):  
Marcel Rozencweig ◽  
Charlotte Sanders ◽  
William Rombaut ◽  
Nadine Crespeigne ◽  
Yvon Kenis ◽  
...  

1986 ◽  
Vol 22 (8) ◽  
pp. 921-926 ◽  
Author(s):  
Werner Scheithauer ◽  
Daniel D. von Hoff ◽  
Gary M. Clark ◽  
Joan L. Shillis ◽  
Edward F. Elslager

Sign in / Sign up

Export Citation Format

Share Document